Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis
This article was originally published in The Pink Sheet Daily
Executive Summary
After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.
You may also be interested in...
Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.
Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates
First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.
Ambrx Inks Three-Target Deal With Wyeth To Develop Antibody-Toxin Conjugates
First license deal for Ambrx's EuCode technology offers potential for "silver bullet" therapeutics that localize pharmacologic activity.